This study aimed to evaluate the effects of short-term (60-d) oral supplementation with calcium fructoborate, resveratrol, and their combination on the clinical and biological statuses of subjects with stable angina pectoris. A randomized, double-blinded, active-controlled, parallel clinical trial was conducted in three groups of subjects. Of the total number of subjects included in study (n = 166), 87 completed the 60-d test treatment study period and 29 followed in parallel their usual medical care and treatment. The primary outcomes were inflammation biomarkers (high-sensitivity C-reactive protein), left ventricular function markers (N-terminal prohormone of brain natriuretic peptide), and lipid markers (total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triacylglycerols). Quality of life was assessed by the Canadian Cardiovascular Society angina class and the number of angina attacks per week. There was a significant decrease of high-sensitivity C-reactive protein in all groups at the 30-d and 60-d visits. This decrease was greater (39.7% at 60 d) for group 3 (calcium fructoborate), followed by group 2 (resveratrol plus calcium fructoborate, 30.3% at 60 d). The N-terminal prohormone of brain natriuretic peptide was significantly lowered by resveratrol (group 1, 59.7% at 60 d) and by calcium fructoborate (group 3, 52.6% at 60 d). However, their combination (group 2) was the most effective and induced a decrease of 65.5%. Lipid markers showed slight changes from baseline in all groups. The improvement in the quality of life was best observed for subjects who received the resveratrol and calcium fructoborate mixture (group 2). The results indicate that the combination of resveratrol and calcium fructoborate has beneficial effects in patients with angina

In the last few years boron (B) compounds became increasingly frequent in the chemotherapy of some forms of cancer with high malignancy and of inoperable cancers. As more B-based therapy chemicals are developed it is necessary to review the correlation between B and the incidence of different forms of cancer, the biochemical and molecular mechanisms influenced by B and to explore the relevance of B in the chemoprevention of cancer. This minireview analyzes dietary and therapeuptic principles based on the chemistry of B compounds. We summarize studies correlating B-rich diets or B-rich environments with regional risks of specific forms of cancers, and studies about the utilization of natural and synthetic B-containing compounds as anticancer agents. We review mechanisms where B-containing compounds interfere with the physiology and reproduction of cancer cells. Types of cancers most frequently impacted by B-containing compounds include prostate, breast, cervical and lung cancer. Mechanisms involving B activity on cancer cells are based on the inhibition of a variety of enzymatic activities, including serine proteases, NAD-dehydrogenases, mRNA splicing and cell division, but also receptor binding mimicry, and the induction of apoptosis. Boron-enriched diets resulted in significant decrease in the risk for prostate and cervical cancer, and decrease in lung cancer in smoking women. Boron-based compounds show promising effects for the chemotheraphy of specific forms of cancer, but due to specific benefits should also be included in cancer chemopreventive strategies.